Edition:
India

Livzon Pharmaceutical Group Inc (1513.HK)

1513.HK on Hong Kong Stock

65.30HKD
7:13am IST
Change (% chg)

HK$-1.00 (-1.51%)
Prev Close
HK$66.30
Open
HK$66.10
Day's High
HK$66.45
Day's Low
HK$65.20
Volume
19,100
Avg. Vol
530,954
52-wk High
HK$68.90
52-wk Low
HK$32.88

Chart for

About

LIVZON PHARMACEUTICAL GROUP INC. is a China-based company principally engaged in research, development, production and distribution of pharmaceutical products. The Company primarily offers western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. The Company’s... (more)

Overall

Beta: 0.64
Market Cap(Mil.): HK$30,110.53
Shares Outstanding(Mil.): 553.23
Dividend: 0.44
Yield (%): 0.98

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Livzon Pharmaceutical Group Says Joincare To Sell 49 PCT Equity Interests In Livzon Mab

* PROPOSES TO ENTER AGREEMENT PURSUANT TO WHICH JOINCARE TO SELL 49% EQUITY INTERESTS IN LIVZON MAB FOR RMB294 MILLION Source text for Eikon: Further company coverage:

18 Jan 2018

REFILE-BRIEF-Livzon Pharmaceutical'ss Board Agrees Unit To Invest $30 Mln In Global Health Science Fund II

* SAYS BOARD AGREES UNIT TO INVEST $30 MILLION IN GLOBAL HEALTH SCIENCE FUND II, L.P. Source text in Chinese: http://bit.ly/2CVb0qK Further company coverage: (Reporting by Hong Kong newsroom)

12 Jan 2018

BRIEF-Livzon Pharmaceutical Group receives subsidy of 12.8 mln yuan

* Says it received subsidy of 12.8 million yuan for injection internationalization and development related projects

10 Jan 2018

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says Zhuhai-based biotechnology unit received drug clinical trial approval for drug named Recombinant Human anti-RANKL Monoclonal Antibody Solution for Injection

02 Jan 2018

BRIEF-Livzon Pharmaceutical Co Announces Change In Shareholding Structure Of Livzon MABPharm

* CO & JOINCARE PHARMACEUTICAL INDUSTRY ENTERED FRAMEWORK AGREEMENT RELATING TO CAPITAL CONTRIBUTION TO LIVZON BIOLOGICS

21 Dec 2017

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for Recombinant Humanized anti-PD-1 Monoclonal Antibody for Injection

03 Nov 2017

BRIEF-Livzon Pharmaceutical's net profits up in Q3, Jan-Sept

* Says Q3 net profit up 1,719.2 percent y/y at 3.7 billion yuan ($556.85 million), 9-month net profit up 590.7 percent y/y at 4.2 billion yuan

25 Oct 2017

BRIEF-Livzon Pharmaceutical sees FY net profit attributable between RMB4.32 bln - RMB4.48 bln

* Sees FY net profit attributable between RMB4.32 billion - RMB4.48 billion Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Livzon Pharmaceutical Group units receive approval for drug clinical trials

* Says its units received drug clinical trials approval for drug, Triptorelin Acetate Microspheres for Injection

18 Sep 2017

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for antineoplastic, Paclitaxel polymeric micelles for injection

11 Sep 2017

Earnings vs. Estimates